Brief: Basilea Reports Positive Interim Results From Phase 2 Study Fides-01 For Derazantinib In FGFR2 Gene Mutation

Basilea Pharmaceutica AG, Allschwil

24/03/2021 06:18

March 24 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * BASILEA REPORTS POSITIVE INTERIM RESULTS FROM PHASE 2
STUDY
FIDES-01 FOR DERAZANTINIB IN FGFR2 GENE MUTATION- OR
AMPLIFICATION-POSITIVE PATIENTS WITH BILE DUCT CANCER (ICCA)
    * EFFICACY DATA OBTAINED IN INTERIM ANALYSIS MET
PRE-SPECIFIED
THRESHOLD SO THAT STUDY WILL PROCEED TO NEXT STAGE AS PLANNED

Source text for Eikon:  ID:nGNE7wbs1G 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))